Exagen Inc.

DB:E08A Stock Report

Market Cap: €87.3m

Exagen Management

Management criteria checks 3/4

Exagen's CEO is John Aballi, appointed in Oct 2022, has a tenure of 2.17 years. total yearly compensation is $931.95K, comprised of 56.3% salary and 43.7% bonuses, including company stock and options. directly owns 1.93% of the company’s shares, worth €1.68M. The average tenure of the management team and the board of directors is 2 years and 5 years respectively.

Key information

John Aballi

Chief executive officer

US$932.0k

Total compensation

CEO salary percentage56.3%
CEO tenure2.2yrs
CEO ownership1.9%
Management average tenure2yrs
Board average tenure5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Aballi's remuneration changed compared to Exagen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$17m

Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$932kUS$525k

-US$24m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$35m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$1mUS$111k

-US$47m

Compensation vs Market: John's total compensation ($USD931.95K) is above average for companies of similar size in the German market ($USD469.36K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Aballi (39 yo)

2.2yrs

Tenure

US$931,950

Compensation

Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022 and served as its Interim Chief Financial Officer since August 2024 until August 31, 2024. Mo...

Leadership Team

NamePositionTenureCompensationOwnership
Tina Nova
Executive Chairman of the Board of Directors5.4yrsUS$132.81k0%
€ 0
John Aballi
CEO, President & Director2.2yrsUS$931.95k1.93%
€ 1.7m
Kamal Adawi
Corporate Secretary7.3yrsUS$915.09k0.30%
€ 260.4k
Jeffrey Black
Chief Financial Officerless than a yearno data1.56%
€ 1.4m
Ryan Douglas
Investors Relations Officerno datano datano data
Andrew Concoff
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board2.2yrsno datano data
Michael Nerenberg
Chief Medical Officer1.6yrsno datano data

2.0yrs

Average Tenure

55yo

Average Age

Experienced Management: E08A's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Tina Nova
Executive Chairman of the Board of Directors5.4yrsUS$132.81k0%
€ 0
John Aballi
CEO, President & Director2.2yrsUS$931.95k1.93%
€ 1.7m
Andrew Concoff
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board5yrsno datano data
Kenneth Bloom
Member of Breast Cancer Advisory Boardno datano datano data
Mark Pegram
Member of Breast Cancer Advisory Boardno datano datano data
Bruce Robertson
Independent Director5.4yrsUS$33.75kno data
Thomas Williams
Member of Breast Cancer Advisory Boardno datano datano data
Michael Press
Member of Breast Cancer Advisory Boardno datano datano data
Lyndsay Harris
Member of Breast Cancer Advisory Boardno datano datano data
Arthur Weinstein
Chairman of Scientific Advisory Board5yrsUS$130.00kno data
Ana Hooker
Independent Director3.4yrsUS$84.20k0%
€ 0
Frank Stokes
Independent Director3.5yrsUS$82.70k0%
€ 0

5.0yrs

Average Tenure

61yo

Average Age

Experienced Board: E08A's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 01:24
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Exagen Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Kyle MiksonCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.